Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SNP genotyping data from human iPSCs and human fibroblast cells

ABSTRACT: Human induced pluripotent stem cells changed the face of stem cell biology as they represent a renewable source of stem cells with the potential to differentiated into multiple lineages in a manner akin to embryonic stem cells that can be collected without the need for the destruction of an embryo. The potential of these cells as research tools is vast as they can be pushed to generate different cell types depending on research interest. Many complex diseasese.g. late onset alzheimer's disease and type 2 diabetes have known genetic risk factors that increase the likelihood of developing a disease. We performed whole genome SNP analysis to examine risk loci for different complex diseases in our donor iPS cells toanalyse disease risk and also assess which donor represents the best healthy background. Genomic DNA was isolated from human induced pluripotent stem cells from 3 donors and fibroblasts from an additional donor for genome-wide SNP analysis. This study was completed using the Affymetrix human genome-wide array 6.0 and analysed using the Affymetrix Genotyping Console Birdseed V2 algorithm.

ORGANISM(S): Homo sapiens

SUBMITTER: Jun Wei

PROVIDER: E-GEOD-61769 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

SNP genotyping data from human iPSCs and human fibroblast cells

Project description:Human induced pluripotent stem cells changed the face of stem cell biology as they represent a renewable source of stem cells with the potential to differentiated into multiple lineages in a manner akin to embryonic stem cells that can be collected without the need for the destruction of an embryo. The potential of these cells as research tools is vast as they can be pushed to generate different cell types depending on research interest. Many complex diseasese.g. late onset alzheimer's disease and type 2 diabetes have known genetic risk factors that increase the likelihood of developing a disease. We performed whole genome SNP analysis to examine risk loci for different complex diseases in our donor iPS cells toanalyse disease risk and also assess which donor represents the best healthy background.

2014-09-26 | GSE61769 | GEO

Gene expression data from human induced pluripotent stem cells and induced pluripotent stem cell-derived human neural progenitor cells

Project description:Embryonic stem cells are pluripotent and possess the ability to differentiate into numerous lineages during the developmental process. In similarity to embryonic stem cells, human induced pluripotent stem cells (iPSCs) possess the potential to differentiate into multiple lineages making them an excellent research tool. We generated iPSCs from multiple donors and also differentiated iPSCs from these donors into human neural progenitor cells (NPCs). We used human transcriptome arrays to detail the programme of gene expression underlying NPC induction and identified distinct classes of up-regulated genes during this process. Total RNAs were extracted from human induced pluripotent stem cells and induced pluripotent stem cell-derived neural progenitor cells. Their gene expression profiles were investigated using the Affymetrix GeneChip Human Transcriptome Array 2.0 platform.

2014-09-12 | E-GEOD-61358 | biostudies-arrayexpress

Transcriptional analysis of pre and post excision human induced pluripotent stem cells

Project description:Transcriptional analysis was performed on pre and post excision human induced pluripotent stem cells, the donor human dermal fibroblasts (HDFs) they were derived from and control human embryonic stem cells We isolated total RNA from pre and post excision human induced pluripotent stem cells, the donor human dermal fibroblasts (HDFs) they were derived from and control human embryonic stem cells and analyzed via Affymetrix microarray analysis.

2013-07-13 | E-GEOD-48830 | biostudies-arrayexpress

Versatile human cardiac tissues engineered with perfusable heart extracellular microenvironment for biomedical applications

Project description:Engineered human cardiac tissues have been utilized for various biomedical applications, including drug testing, disease modeling, and regenerative medicine. However, the applications of cardiac tissues derived from human pluripotent stem cells are often limited due to their immaturity and lack of functionality. Therefore, in this study, we established a perfusable culture system based on in vivo-like heart microenvironments to improve human cardiac tissue fabrication. The integrated culture platform of a microfluidic chip and a three-dimensional heart extracellular matrix enhanced human cardiac tissue development and their structural and functional maturation. These tissues were comprised of cardiovascular lineage cells, including cardiomyocytes and cardiac fibroblasts derived from human induced pluripotent stem cells, as well as vascular endothelial cells. The resultant macroscale human cardiac tissues exhibited improved efficacy in drug testing (small molecules with various levels of arrhythmia risk), disease modeling (long QT syndrome and cardiac fibrosis), and regenerative therapy (myocardial infarction treatment). Therefore, our culture system can serve as a highly effective tissue-engineering platform to provide human cardiac tissues for versatile biomedical applications.

2024-02-03 | PXD042077 | Pride

Metabolomics Workbench ST000003 - GNPS - Metabolomic analysis of mouse embryonic fibroblasts, embryonic stem cells, and induced pluripotent stem cells

Project description:mouse embryonic fibroblasts, embryonic stem cells, and induced pluripotent stem cells were compared via metabolomic analysis

2018-08-02 | MSV000082680 | GNPS

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Project description:This phase I trial studies the side effects and best dose of genetically modified T-cells following peripheral blood stem cell transplant in treating patients with recurrent or high-risk non-Hodgkin lymphoma. Giving chemotherapy before a stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body’s normal cells. Removing the T cells from the donor cells before transplant may stop this from happening. Giving an infusion of the donor’s T cells (donor lymphocyte infusion) later may help the patient’s immune system see any remaining cancer cells as not belonging in the patient’s body and destroy them (called graft-versus-tumor effect)

| 2141916 | ecrin-mdr-crc

Platform for Induction and Maintenance of Transgene-Free hiPSCs Resembling Ground State Pluripotent Stem Cells

Project description:The purpose of this series of experiments is to identify copy number variations, duplications, deletions and regions of homozygosity in human induced pluripotent stem (hiPSC) cell lines. Genomic DNA of human induced pluripotent stem cell lines are extracted and hybridized to Agilent aCGH+SNP microarray, using genotyped Agilent Reference DNA as common reference. Differences and similarities between fibroblast and stem cell lines will be revealed.

2014-03-03 | E-GEOD-54080 | biostudies-arrayexpress

Genome-wide analysis of the gene expression profile of in vivo induced pluripotent stem cells

Project description:Analysis of the gene expression profile of a novel type of pluripotent stem cells (in vivo induced pluripotent stem cells, named i2PS cells) obtained by reprogramming BALB/c mice hepatocytes in vivo. The hypothesis tested in the present study is that in vivo induced pluripotent stem cells will have a similar gene expression profile to that of other pluripotent stem cells. Hence the embryonic stem cell line E14TG2A is used as a reference in this study. Results provide valuable information for the overall molecular characterisation of cells that have been reprogrammed to pluripotency in vivo, together with the confirmation of their pluripotent character at the gene expression level. Total RNA was obtained from i2PS and E14TG2A cells cultured under standard embryonic stem cells conditions (i.e. DMEM supplemented with LIF). Three biological replicates were included for each cell type. Data were analysed using the gene expression levels of E14TG2A cells as a reference.

2014-03-19 | E-GEOD-55996 | biostudies-arrayexpress

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Project description:This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient’s immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor’s T cells (donor lymphocyte infusion) after the transplant may help increase this effect.

| 2143763 | ecrin-mdr-crc

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Project description:RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient’s immune system from rejecting the donor’s stem cells. The donated stem cells may replace the patient’s immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body’s normal cells. Giving tacrolimus, sirolimus, antithymocyte globulin, and methotrexate before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well sirolimus, tacrolimus, and antithymocyte globulin work in preventing graft-versus-host disease in patients undergoing a donor stem cell transplant for hematological cancer .

| 2048717 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data